arrow
E

Edoardo Pescarmona

pathology unit
H指数:43
被引数:6,748

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Unlocking personalized endometrial cancer treatment: the critical role of the BBIRE biobank in sample collection and distribution

解锁个性化子宫内膜癌治疗:BBIRE生物样本库在样本收集和分发中的关键作用

2026-02-120
OAAI
Biopsy RNA-seq captures TROP-2–linked migration and clonal resistance to forecast aggressiveness in metastatic melanoma
2026-01-280
OAAI
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B (vol 23, pg 1379, 2022)

I型ifn通过触发表观遗传调节因子KDM1B促进癌细胞干细胞性 (第23卷,1379页,2022页)

2024-09-170
OAAI
The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

里贾纳·埃琳娜国家癌症研究所的分子肿瘤委员会: 从应计到现实世界的治疗

2023-10-164
OAAI
Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma
2023-03-0112
OAAI
Type I IFNs promote cancer cell stemness by triggering the epigenetic regulator KDM1B

I型ifn通过触发表观遗传调节因子KDM1B促进癌细胞干细胞性

2022-08-2467
OAAI
Characterizing the tumor microenvironment in rare renal cancer histological types

罕见肾癌组织学类型的肿瘤微环境特征

2021-10-0711
OAAI
METTL3-dependent MALAT1 delocalization drives c-Myc induction in thymic epithelial tumors
2021-09-1626
OAAI
Multicohort and cross-platform validation of a prognostic Wnt signature in colorectal cancer

结直肠癌预后Wnt签名的多端口和跨平台验证

2020-12-291
OAAI
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden

尽管肿瘤突变负担高,但对免疫疗法无反应的肺腺癌中的KEAP1-driven共突变

2020-12-01168
OAAI
LINC00174 is a novel prognostic factor in thymic epithelial tumors involved in cell migration and lipid metabolism
2020-11-0728
OAAI
Diagnostic and Clinical Impact of 18F-FDG PET/CT in Staging and Restaging Soft-Tissue Sarcomas of the Extremities and Trunk: Mono-Institutional Retrospective Study of a Sarcoma Referral Center

18F-FDG PET/CT在四肢和躯干软组织肉瘤分期和再修复中的诊断和临床影响: 肉瘤转诊中心的单机构回顾性研究

2020-08-0619
OAAI